ArticleAmerican journal of preventive cardiology2026

Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.

Liffert Vogt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.